Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients;Discrepancias entre documentos de consenso, guías, práctica clínica y normativa legal en el tratamiento de los pacientes con diabetes mellitus tipo 2

Nefrologia

Volumn 32, Issue 3, 2012, Pages 367-373

  del Pozo Fernández, Carlos ^a   Pardo Ruiz, Carlos ^a   Sánchez Botella, Concepción ^b   Blanes Castañer, Vanesa ^a   López Menchero, Ramón ^a   Gisbert Sellés, Cristina ^b   Sánchez Jodar, Carmen ^a   Álvarez Avellán, Luis ^a  

^a HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^b MEDICINA FAMILIAR Y COMUNITARIA   (Spain)

Author keywords

Chronic kidney disease; Consensus documents; Diabetes mellitus; Guidelines; Legal framework; Metformin

Indexed keywords

ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; METFORMIN; PIPERIDINE DERIVATIVE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CONSENSUS DEVELOPMENT; DIABETIC NEPHROPATHY; DISEASE MANAGEMENT; DRUG CONTRAINDICATION; DRUG UTILIZATION; ENDOCRINOLOGY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITAL DEPARTMENT; HUMAN; LACTIC ACIDOSIS; LEGAL ASPECT; MALE; MEDICAL SOCIETY; METABOLISM; MIDDLE AGED; NEPHROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROFESSIONAL PRACTICE; SPAIN; STANDARD; STATISTICS;

ACIDOSIS, LACTIC; AGED; CARBAMATES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; DRUG UTILIZATION; ENDOCRINOLOGY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HOSPITAL DEPARTMENTS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NEPHROLOGY; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROFESSIONAL PRACTICE; SOCIETIES, MEDICAL; SPAIN; SULFONYLUREA COMPOUNDS;

EID: 84864527043     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Jan.11244     Document Type: Article

References (30)

1. Menéndez-Torre E, Lafita Tejedor J, Artola Menéndez S, Millán Núñez-Cortes J, Alonso García A, Puig Domingo M, et al. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes mellitus tipo 2. Av Diabetol 2010;26:331-8.
2. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grumberger G, et al. Statement by an American association of clinical endocrinologist consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. AACE/ACE Consensus Statement. Endocr Pract 2009;15:540-59.
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
4. Harper W, Hanna A, Woo V, Dawson KG, Yale JF, MacCallum L, et al. Pharmacologic Management of type 2 diabetes. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008;32:S53-60.
5. National evidence based guidelines for blood glucose control in type 2 diabetes. Available at: http://www.nhmrc.gov.au/-_files_nhmrc/publications/attachments/di19-diabetes-blood-glucosecontrol. pdf. [Accessed: november 12, 2011].
6. UK prospective Diabetes Study Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
7. Sáenz Calvo A, Fernández Esteban I, Mataix Sanjuan A, Ausejo Segura M, Roqué M, Moher D. Metformin for type 2 diabetes mellitus. Sistematic Review and Meta-analysis. Aten Primaria 2005;36:1-9.
8. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin treated NIDDM patients with suboptimal control. Diabetes Care 1996;19:701-5.
9. Ficha técnica metformina. Vademécum Agencia Española del Medicamento. https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=det alleForm. [Accessed: november 7, 2011].
10. Levey AS, Greene T, Kusec JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;Suppl 11: A1828.
11. Ley 29/2006/26 julio de Garantías y uso racional de los medicamentos y productos sanitarios. Available at: http://noticias.juridicas.com/base_datos/Admin/l292006.html. [Accessed: november 7, 2011].
12. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morrist AD, for the DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes a populationbased study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.
13. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004;180:53-4.
14. Philbrick AM, Ernst ME, McDanel D, Ross MB, Moores KG. Metformin use in renal dysfunction: is a serum creatinine threshold appropiate? Am J Health Syst Pharm 2009;66:2017-23.
15. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and no fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev Available at: http://updatesoftware. com. CD002967.2006.
16. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99.
17. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 2008;31:2086-91.
18. Hosltein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48:2454-9.
19. Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol 2008;40:411-7.
20. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7.
21. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
22. Marín R, Goicoechea MA, Gorostidi M, et al. Guías SEN. Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad cardiovascular. Versión abreviada. 2006;26:31-44.
23. Stevens LA, Coresh J, Greene T, Levey AS. Assesing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
24. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007;18:2749-57.
25. Gracia S, Montañés R, Bover J, Cases A, Deulofeu R, Martín de Francisco AL, et al. Documento de consenso: recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. Nefrologia 2006;26:658-65.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
27. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR threshold to guide metformin prescribing. Diabet Med 2007;24:1160-3.
28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate filtration rate. Ann Intern Med 2009;150:604-12.
29. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60/ml/min/1.73m2. Am J Kidney Dis 2010;56:486-95.
30. Stevens LA, Li S, Tamura MK, Chen SC, Vassalotti JA, Norris KC, et al. Comparison of CKD awareness in a screening population using the modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations. Am J Kidney Dis 2010;57:S17-23